Information on the Audit and Risk Committee, Remuneration Committee, Nomination Committee and R&D Committee.
|Member||Audit and Risk Committee||Remuneration Committee||Nomination and Corporate Governance Committee||R&D Committee|
|Dr. Peter Fellner||X|
|Dr. Jeremy Bender||X|
|Dr. Anders Ekblom||X||X||X|
|Dr. Deepa Pakianathan||X||X|
|Dr. Brian Schwartz||X|
The Audit and Risk Committee is made up of three non-executive directors, comprising Mr Wyzga (Chair), Dr Bender and Mr Kashyap. Mr Wyzga is considered an "audit committee financial expert" as defined by applicable SEC rules and each of the members has the requisite financial sophistication as defined under the applicable Nasdaq rules and regulations.
The Audit and Risk Committee meets at least four times a year within the appropriate reporting and audit cycle. The Committee’s responsibilities include monitoring the financial integrity of the financial statements of the Mereo Group, communication with the Group’s auditor, reviewing the effectiveness of Mereo Group’s internal control systems and risk management systems and overseeing the process for managing risks across the Mereo Group. The Audit and Risk Committee will meet at least once per year with the Group’s independent accountant without the Mereo Group’s senior management being present.
The Audit and Risk Committee focuses in particular on compliance with legal requirements, accounting standards and the rules of the SEC and ensuring that an effective system of internal financial control is maintained. The ultimate responsibility for reviewing and approving the annual report and accounts and the half-yearly reports, remains with the Board of Directors of Mereo BioPharma.
The Remuneration Committee is made up of three non-executive directors, comprising Mr Bains (Chair), Dr Ekblom and Dr Pakianathan.
The Remuneration Committee, meets at least two times a year, has responsibility for the determination of specific remuneration packages for each of the Executive Directors and any applicable senior executives of the Mereo Group. This includes bonuses, any pension rights and any other compensation payments and the implementation of share option, or other performance related, schemes.
The Nomination and Corporate Governance Committee is made up of three members, comprising Dr Fellner (Chair), Mr Bains and Dr Ekblom. The Nomination Committee meets at least twice a year.
The Nomination and Corporate Governance Committee is responsible for considering and making recommendations to the Board in respect of appointments to the Board. It is also responsible for keeping the structure, size and composition of the Board under regular review, and for making recommendations to the Board with regard to any changes necessary. The Nomination and Corporate Governance Committee also considers succession planning and composition of the Board committees.
The Research and Development Committee is made up of four members, comprising Dr Ekblom (Chair), Mr Bains, Dr Pakianathan and Dr Schwartz.
The Research and Development Committee meets at least twice a year and provides oversight of the research and development activities of the Company. This includes overseeing strategic development plans for products in the Company’s portfolio and providing input to the acquisition of new products. The Committee is also tasked with keeping up-to-date with the competitive landscape that may affect the Company’s research and development and commercial activities, and providing guidance and making recommendations to the Board in respect of such activities.